84.66
price down icon1.62%   -1.39
after-market  After Hours:  84.66 
loading
Haemonetics Corp. stock is currently priced at $84.66, with a 24-hour trading volume of 338.62K. It has seen a -1.62% decreased in the last 24 hours and a -13.05% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $85.50 pivot point. If it approaches the $84.64 support level, significant changes may occur.
Previous Close:
$86.05
Open:
$85.44
24h Volume:
338.62K
Market Cap:
$4.31B
Revenue:
$1.27B
Net Income/Loss:
$126.57M
P/E Ratio:
34.00
EPS:
2.49
Net Cash Flow:
$128.75M
1W Performance:
-1.11%
1M Performance:
-13.05%
6M Performance:
-4.62%
1Y Performance:
+0.02%
1D Range:
Value
$84.26
$85.59
52W Range:
Value
$70.74
$97.97

Haemonetics Corp. Stock (HAE) Company Profile

Name
Name
Haemonetics Corp.
Name
Phone
781-848-7100
Name
Address
400 Wood Road, Braintree, MA
Name
Employee
3,136
Name
Next Earnings Date
2024-05-09
Name
Latest SEC Filings
Name
HAE's Discussions on Twitter

Haemonetics Corp. Stock (HAE) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-13-22 Initiated Mizuho Buy
Jan-27-22 Downgrade Needham Buy → Hold
Dec-15-21 Downgrade Citigroup Buy → Neutral
Aug-17-21 Resumed Raymond James Outperform
Jun-17-21 Initiated Citigroup Buy
May-14-21 Upgrade CJS Securities Market Perform → Market Outperform
Apr-20-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-19-21 Downgrade CJS Securities Market Outperform → Market Perform
Feb-03-21 Upgrade Barrington Research Mkt Perform → Outperform
Jan-21-21 Downgrade Barrington Research Outperform → Mkt Perform
Nov-05-20 Upgrade Barrington Research Mkt Perform → Outperform
May-06-20 Downgrade Barrington Research Outperform → Mkt Perform
Mar-31-20 Upgrade CJS Securities Market Perform → Market Outperform
Jan-10-20 Initiated Needham Buy
Aug-07-19 Reiterated Barrington Research Outperform
May-14-19 Upgrade Raymond James Mkt Perform → Outperform
May-08-19 Reiterated Barrington Research Outperform
Aug-09-18 Reiterated Barrington Research Outperform
Feb-07-18 Reiterated Barrington Research Outperform
Jan-02-18 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-08-17 Reiterated Barrington Research Outperform
Aug-08-17 Upgrade Barrington Research Mkt Perform → Outperform
Jul-13-17 Upgrade JMP Securities Mkt Perform → Mkt Outperform
Feb-07-17 Downgrade Barrington Research Outperform → Mkt Perform
Nov-08-16 Upgrade Barrington Research Mkt Perform → Outperform
Nov-07-16 Reiterated The Benchmark Company Hold
Sep-20-16 Downgrade CJS Securities Market Outperform → Market Perform
Aug-15-16 Downgrade Sidoti Buy → Neutral
Aug-02-16 Reiterated Jefferies Buy
Aug-02-16 Reiterated The Benchmark Company Hold
View All

Haemonetics Corp. Stock (HAE) Financials Data

Haemonetics Corp. (HAE) Revenue 2024

HAE reported a revenue (TTM) of $1.27 billion for the quarter ending December 31, 2023, a +12.48% rise year-over-year.
loading

Haemonetics Corp. (HAE) Net Income 2024

HAE net income (TTM) was $126.57 million for the quarter ending December 31, 2023, a +32.18% increase year-over-year.
loading

Haemonetics Corp. (HAE) Cash Flow 2024

HAE recorded a free cash flow (TTM) of $128.75 million for the quarter ending December 31, 2023, a +0.50% increase year-over-year.
loading

Haemonetics Corp. (HAE) Earnings per Share 2024

HAE earnings per share (TTM) was $2.46 for the quarter ending December 31, 2023, a +32.97% growth year-over-year.
loading
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. The company also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, it offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, a surgical blood salvage system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; OrthoPAT, a perioperative autotranfusion system for orthopedic procedures; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.
medical_instruments_supplies ATR
$144.75
price down icon 0.74%
medical_instruments_supplies TFX
$208.29
price down icon 0.48%
$71.79
price down icon 0.49%
medical_instruments_supplies BAX
$33.78
price up icon 0.12%
medical_instruments_supplies COO
$93.47
price down icon 0.77%
medical_instruments_supplies WST
$333.25
price down icon 0.90%
Cap:     |  Volume (24h):